Pandemic (H1N1) 2009 Influenza
For more information about CSL's Pandemic H1N1 vaccine please visit
www.h1n1vax.com.au
Background on CSL's Pandemic H1N1 vaccine.
CSL, Australia’s leading biopharmaceutical company, is the only commercial manufacturer of influenza vaccines in the Southern Hemisphere. As such we have been contracted by the Australian Government to supply 21 million doses of pandemic H1N1 vaccine, in a global environment where demand for influenza vaccines greatly exceeds supply.
CSL is manufacturing a pandemic H1N1 influenza vaccine called Panvax
®H1N1 which uses the proven technology that has enabled us to provide Australia with seasonal flu vaccines over the last 40 years. This technology is also used by the majority of influenza vaccine manufacturers around the world. The process used to manufacture Panvax
®H1N1 vaccine is essentially the same as the process used to manufacture influenza vaccines used to prevent seasonal flu.
To facilitate the distribution and supply of a large number of doses, the vaccine will be supplied primarily in multi-dose vials. It is a requirement that multi-dose vials contain a preservative to maintain sterility. Flu vaccines are routinely supplied in preservative-containing multi-dose vials in other countries eg the United States.
Further information on Panvax
®H1N1 can be found on the H1N1vax website
www.h1n1vax.com.au